Efficacy of epetraborole against Mycobacteroides abscessus in a mouse model of lung infection
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00648-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Binayak Rimal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Disease Models, Animal, Mycobacterium Infections, Nontuberculous, Anti-Bacterial Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, AN2 Therapeutics Inc, HHS | National Institutes of Health (NIH).
Abstract (Originalsprache)
Mycobacteroides abscessus ( Mab or Mycobacterium abscessus ) is a fast-growing mycobacterium that is ubiquitous in the environment and can cause opportunistic disease in people with lung comorbidity and immunodeficiency. There are no Food and Drug Administration-approved drugs for this disease, and repurposed antibiotics have a poor microbiological response. To address the need for effective new antibiotics, we determined the efficacy of epetraborole (EBO) against three Mab clinical isolates in a mouse model of lung Mab infection. Reduction in lung Mab burden over 4 weeks of treatment was the study end point. EBO was administered orally once daily at doses of 25 and 50 mg/kg, which achieved exposures approximating the once-daily dosing of 250 mg and 500 mg, respectively, in humans. EBO administration led to a gradual reduction in the lung Mab burden. After 4 weeks of treatment, the efficacies of 25 and 50 mg/kg EBO against isolates ATCC 19977 and M9501 were comparable. However, against isolate M9530, 50 mg/kg EBO was more efficacious than 25 mg/kg and comparable with parenteral imipenem, one of the most efficacious antibiotics against Mab . We also undertook a dose-ranging study by evaluating the efficacies of once-daily oral administration of 0.5, 5, 10, 25, and 100 mg/kg EBO against M9501 over 4 weeks. Once-daily oral 100 mg/kg EBO was as effective as twice-daily 100 mg/kg imipenem injection. Our study suggests that EBO could address the unmet need for effective oral treatment options for Mab lung disease, given the high rates of Mab drug resistance and limited tolerable intravenous options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
- Center for Nontuberculous Mycobacteria and Bronchiectasis, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
- AN2 Therapeutics, Inc., Menlo Park, California, USA.
ORCID-Profile: Gyanu Lamichhane
Förderung
- NIAID NIH HHS
- AN2 Therapeutics Inc
- HHS | National Institutes of Health (NIH)
Zitieren
APA
Rimal, B., Lippincott, C. K., Panthi, C. M., Xie, Y., Keepers, T. R., Alley, M., & Lamichhane, G. (2024). Efficacy of epetraborole against Mycobacteroides abscessus in a mouse model of lung infection. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00648-24
Vancouver
Rimal B, Lippincott CK, Panthi CM, Xie Y, Keepers TR, Alley M, et al. Efficacy of epetraborole against Mycobacteroides abscessus in a mouse model of lung infection. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00648-24
BibTeX
@article{Rimal2024,
author = {Rimal, Binayak and Lippincott, Christopher K and Panthi, Chandra M and Xie, Yi and Keepers, Tiffany R and Alley, Mrk and Lamichhane, Gyanu},
title = {Efficacy of epetraborole against Mycobacteroides abscessus in a mouse model of lung infection},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00648-24}
}
EUVIMED